argenx SE (FRA:1AE)

Market Cap	47.19B
Revenue (ttm)	3.14B
Net Income (ttm)	1.31B
Shares Out	n/a
EPS (ttm)	19.83
PE Ratio	36.11
Forward PE	31.15
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	5
Open	785.40
Previous Close	798.40
Day's Range	785.40 - 785.40
52-Week Range	448.40 - 804.40
Beta	n/a
RSI	61.71
Earnings Date	Feb 26, 2026

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 1,599
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1AE

Financial Performance

Financial numbers in USD